

IFW

# CERTIFICATE OF MAILING



I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: Katie Holland

Signature: Katie Holland Date: 4/10/06

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Supplemental Information Disclosure Statement</b>  <b>Address to:</b> <b>Commissioner of Patents</b> <b>PO Box 1450</b> <b>Alexandria, VA 22313-1450</b>	<b>First Inventor</b>	<b>Charles Alis Dvorak</b>
	<b>Application Number</b>	<b>10/685,124</b>
	<b>Filing Date</b>	<b>October 14, 2003</b>
	<b>Group Art Unit</b>	<b>1624</b>
	<b>Examiner</b>	<b>Deepak R. Rao</b>
	<b>Attorney Docket No.</b>	<b>R0067D-DIV</b>
	<b>Title</b>	<b>Heterocyclalkyl amines As Muscarinic Receptor Antagonists</b>

Sir:

### Transmittal Letter for Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner references cited in the Japanese patent application that is a counterpart of the subject application. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application.

- [X] Attached with this Transmittal Letter are:
- (a) Information Disclosure Statement Form 1449;
  - (b) Copies of references cited;
  - (c) Certificate of Mailing;
  - (d) Return postcard.
- [X] The Information Disclosure Statement is being submitted before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**
- [X] Additionally, the undersigned hereby certifies under 37 C.F.R. 1.97(e)(1) that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office on a counterpart foreign application not more than three (3) months prior to the filing of the Information Disclosure Statement. **Therefore, no fee is due.**

- [X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



---

Robert C. Hall  
Reg. No. 39,209  
Attorney for Applicants

Roche Palo Alto  
Patent Law Dept. M/S A2-250  
3431 Hillview Avenue  
Palo Alto, CA 94304  
Direct Phone (650) 354-7540

Date: Apr. 10 2006



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTS**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/685,124
Filing Date	October 14, 2003
First Named Inventor	Charles Alis Dvorak
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	R0067D-DIV

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Name of Patentee and/or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Name of Patentee and/or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY		
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C14	REIFFEN, et al., "Specific Bradycardic Agents. 1. Chemistry, Pharmacology, and Structure-Activity Relationships of Substituted Benzazepinones, a New Class of Compounds Exerting Antiischemic Properties", <u>J. Med. Chem.</u> , 1988, pp. 55-72, Vol. 36	
	C15	TAKEDA, "Effects of the Bradycardic Agents, Alinidine and Falipamil on Atrio- ventricular Conduction" <u>Shinshu Medical Journal</u> , 1988, pp. 55-72, Vol. 36, No. 1	
Examiner Signature			Date Considered

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.